Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA + arsenic + venetoclax for newly diagnosed adult high-risk APL
ChiCTR2600123520Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tretinoin, arsenic trioxide and venetoclax in Acute promyelocytic leukaemia (APL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Overall survival at 3 months. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
tretinoinarsenic trioxidevenetoclax
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR2600123520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123520.